Piper Sandler Increases Hims & Hers Health (NYSE:HIMS) Price Target to $13.00

Hims & Hers Health (NYSE:HIMS) had its price target hoisted by research analysts at Piper Sandler from $11.00 to $13.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Piper Sandler’s price objective would suggest a potential upside of 6.91% from the stock’s current price.

A number of other analysts also recently weighed in on HIMS. Truist Financial upped their target price on Hims & Hers Health from $10.00 to $13.00 and gave the company a “hold” rating in a research report on Tuesday, February 27th. Guggenheim raised their target price on shares of Hims & Hers Health from $15.00 to $17.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Canaccord Genuity Group began coverage on shares of Hims & Hers Health in a report on Wednesday, April 10th. They set a “buy” rating and a $20.00 price target for the company. Canaccord Genuity Group initiated coverage on shares of Hims & Hers Health in a research note on Wednesday, April 10th. They issued a “buy” rating and a $20.00 price objective on the stock. Finally, Jefferies Financial Group restated a “hold” rating and set a $15.00 price objective (down from $17.00) on shares of Hims & Hers Health in a research report on Tuesday, April 16th. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Hims & Hers Health presently has a consensus rating of “Moderate Buy” and an average target price of $15.07.

Hims & Hers Health Stock Down 1.5 %

Shares of HIMS stock opened at $12.16 on Tuesday. The company has a market capitalization of $2.61 billion, a PE ratio of -107.91 and a beta of 0.97. Hims & Hers Health has a 12-month low of $5.65 and a 12-month high of $17.16. The firm has a 50 day moving average price of $14.01 and a two-hundred day moving average price of $10.39.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, May 6th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The business had revenue of $278.20 million for the quarter, compared to analyst estimates of $270.37 million. During the same period last year, the firm earned ($0.05) earnings per share. Hims & Hers Health’s revenue for the quarter was up 45.8% compared to the same quarter last year. As a group, research analysts expect that Hims & Hers Health will post 0.11 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Andrew Dudum sold 97,208 shares of Hims & Hers Health stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $9.58, for a total transaction of $931,252.64. Following the sale, the chief executive officer now directly owns 51,653 shares of the company’s stock, valued at $494,835.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, COO Melissa Baird sold 11,750 shares of the stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $12.08, for a total value of $141,940.00. Following the completion of the sale, the chief operating officer now directly owns 538,932 shares in the company, valued at $6,510,298.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Andrew Dudum sold 97,208 shares of the firm’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $9.58, for a total value of $931,252.64. Following the transaction, the chief executive officer now directly owns 51,653 shares of the company’s stock, valued at $494,835.74. The disclosure for this sale can be found here. Insiders sold a total of 736,191 shares of company stock valued at $9,733,700 in the last 90 days. Corporate insiders own 31.63% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds have recently made changes to their positions in the stock. Forerunner Ventures Management LLC acquired a new stake in Hims & Hers Health during the 4th quarter valued at approximately $86,836,000. Vanguard Group Inc. increased its position in shares of Hims & Hers Health by 3.1% during the third quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock worth $88,857,000 after buying an additional 428,671 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Hims & Hers Health by 39.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,272,750 shares of the company’s stock worth $8,006,000 after buying an additional 357,590 shares during the last quarter. Federated Hermes Inc. lifted its holdings in Hims & Hers Health by 38.6% in the third quarter. Federated Hermes Inc. now owns 1,032,452 shares of the company’s stock valued at $6,494,000 after buying an additional 287,552 shares during the period. Finally, Must Asset Management Inc. bought a new stake in Hims & Hers Health during the third quarter valued at $1,596,000. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.